Intravitreal Anti-Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic #MMPMID33331873
Billioti de Gage S; Drouin J; Desplas D; Cuenot F; Dray-Spira R; Weill A; Zureik M
JAMA Ophthalmol 2021[Feb]; 139 (2): 240-242 PMID33331873show ga
This cohort study uses data from the French National Health Data System to assess the decline in the use of intravitreal anti-vascular endothelial growth factors before, during, and after pandemic-associated lockdown periods.